MannKind history

1994 PDC files the first patents for Technosphere® Technology.

In 1997, Al saw the potential of a dry powder insulin formulation to change the way diabetes is treated.

In early 1998, while Mann was presiding over MiniMed’s insulin pump business, a Toronto entrepreneur named John Simard called Mann, looking for help in obtaining pumps for cancer vaccine trials he wanted to begin in Europe.

IND for Technosphere insulin submitted to the United States FDA; PDC relocates to Danbury, CT. 2000

Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

Pondel, Evan, “Valencia, Calif.-based AlleCure Developing Vaccine Against Bee Venom,” Daily News, April 2, 2002.

When Alfred E. Mann turned 79 in 2004, there was little time in his schedule to celebrate his birthday.

The company received approval from the FDA to begin Phase 1 clinical trials of its cancer vaccine at the end of 2006.

2008 Commercial manufacturing facility in Danbury is expanded and renovated.

NDA for Technosphere insulin is submitted to the FDA. 2009

Analysts predicted Technosphere would not reach doctors’ offices until at least 2010.

2011 Additional Phase 3 studies of Technosphere insulin conducted using next-generation inhaler (Dreamboat®).

The FDA approved Afrezza on June 27, 2014.

2015 Formulation work commences on Treprostinil Technosphere (TreT).

On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi.

By December 2017, the company had lost 11% of its trading volume due to the poor sales.

2018 IND for TreT submitted to FDA; Phase 1 clinical study conducted; TreT licensed to United Therapeutics.

In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.